Skip to main content

18F-FMISO PET/CT: a new promising radiotracer for cardiac sarcoidosis and extracardiac involvement?

Dear Editor,

I read with great interest the article entitled “18F-FMISO PET/CT detects hypoxic lesions of cardiac and extracardiac involvement in patients with sarcoidosis”. FMISO is a promising radiotracer because as shown by Furuya et al.1 it has no physiological myocardial uptake and did not require special preparation (low carbohydrate diet at least 24 hours before performing the exam, the fasting state of patient and the difficult glycemic control in diabetic patients). Although the small sample size of the dataset of patients, I think that this tracer could be the future in the diagnostic setting of cardiac sarcoidosis and his extracardiac involvement sites. Further studies also in multicenter controlled trials are needed to confirm this promising results.

References

  1. Furuya S, Naya M, Manabe O, et al. 18F-FMISO PET/CT detects hypoxic lesions of cardiac and extra-cardiac involvement in patients with sarcoidosis. J Nucl Cardiol 2021;28:2141‐8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sara Pacella MD.

Ethics declarations

Disclosures

There is no conflict of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pacella, S. 18F-FMISO PET/CT: a new promising radiotracer for cardiac sarcoidosis and extracardiac involvement?. J. Nucl. Cardiol. (2022). https://doi.org/10.1007/s12350-022-03052-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12350-022-03052-y